A Randomized Controlled Trial Evaluating the Safety and Feasibility of the Recombinant Human Platelet-derived Growth Factor B (rhPDGF-BB)-Enhanced Collagen Plug for Complex Perianal Fistula Healing
The average success rate for healing and remission of complex perianal fistulas, idiopathic or Crohn's-related, is approximately 50%. These abnormal connections between the rectum and the outside skin remain a major clinical challenge in need of new treatments aimed at tissue repair. Platelet-derived growth factor drives wound healing and tissue regeneration, and manufactured PDGF is currently used to heal diabetic foot ulcers and regenerate bone in periodontal and orthopedic patients. Manufactured recombinant human PDGF has the potential to improve the success rate for complete healing of complex perianal fistulas, reduce the recurrence rate due to reopening of the fistula tract, and avoid complications associated with routine surgical interventions.
Indication: Anal Fistula
Modality: small molecule
Target: RhPDGF-BB
Sponsor: Alexander Hawkins
Source URL: ClinicalTrials.gov
Source updated: Jan 21, 2026
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: RhPDGF-BB
View original source fields
Condition raw: Anal Fistula, Complex Perianal Fistula
Condition normalized: Anal Fistula, Complex Perianal Fistula
Modality raw: small molecule
Modality normalized: small molecule
Target raw: RhPDGF-BB
Target normalized: RhPDGF-BB